{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:36:18Z","timestamp":1774895778796,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00228-021-03163-4","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:40:17Z","timestamp":1622590817000},"page":"1665-1672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost effectiveness of antihypertensive drugs and treatment guidelines"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-4664","authenticated-orcid":false,"given":"Marta","family":"Ku\u010dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Luli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasenka Mr\u0161i\u0107","family":"Pel\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Mozeti\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinko","family":"Vitezi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"1","key":"3163_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40292-015-0115-2","volume":"23","author":"F Pistoia","year":"2016","unstructured":"Pistoia F, Sacco S, Degan D, Tiseo C, Ornello R, Carolei A (2016) Hypertension and stroke: epidemiological aspects and clinical evaluation. High Blood Press Cardiovasc Prev 23(1):9\u201318","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"6","key":"3163_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1024\/0040-5930\/a000687","volume":"72","author":"A Handschin","year":"2015","unstructured":"Handschin A, Henny-Fullin K, Buess D, Dieterle T (2015) Cardiovascular risk stratification and therapeutic implications in arterial hypertension. Ther Umsch 72(6):361\u2013368","journal-title":"Ther Umsch"},{"issue":"4","key":"3163_CR3","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"22","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, C\u00edfkov\u00e1 R, Dominiczak AF et al (2018) Hypertension Nat Rev Dis Primers 22(4):18014","journal-title":"Hypertension Nat Rev Dis Primers"},{"issue":"5","key":"3163_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00059-017-4574-1","volume":"42","author":"JA Wermelt","year":"2017","unstructured":"Wermelt JA, Schunkert H (2017) Management of arterial hypertension. Herz 42(5):515\u2013526","journal-title":"Herz"},{"issue":"1","key":"3163_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11154-016-9348-1","volume":"17","author":"J Jordan","year":"2016","unstructured":"Jordan J, Birkenfeld AL (2016) Cardiometabolic crosstalk in obesity-associated arterial hypertension. Rev Endocr Metab Disord 17(1):19\u201328","journal-title":"Rev Endocr Metab Disord"},{"key":"3163_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0025-7125(05)70568-X","volume":"81","author":"J He","year":"1997","unstructured":"He J, Whelton PK (1997) Epidemiology and prevention of hypertension. Med Clin North Am 81:1077\u20131097","journal-title":"Med Clin North Am"},{"key":"3163_CR7","unstructured":"World Health Organisation\u00a0(2019)\u00a0Prevention of cardiovascular disease. Guidance for assessment and management of cardiovascular risk. https:\/\/ish-world.com\/downloads\/activities\/71665_71665_OMS_INT-RETIRATION.pdf, Accessed\u00a028 Nov 2019"},{"key":"3163_CR8","doi-asserted-by":"crossref","unstructured":"Whitworth JA (2003) World Health Organization, International Society of Hypertension Writing Group.  World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 11:1983\u201392.\u00a0Accessed 21 Nov 2003\u00a0","DOI":"10.1097\/00004872-200311000-00002"},{"issue":"7","key":"3163_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jhh.2009.85","volume":"24","author":"RL Antikainen","year":"2010","unstructured":"Antikainen RL, Kastarinen MJ, Jousilahti P, Peltonen M, Laatikainen T, Beckett N et al (2010) Despite evidence-based guidelines, systolic blood pressure remains inadequately controlled in older hypertensive adults. J Hum Hypertens 24(7):439\u2013446","journal-title":"J Hum Hypertens"},{"key":"3163_CR10","unstructured":"Leeder S, Raymond S,  Greenberg H,  Liu H et al (2019)\u00a0A race against time: the challenge of cardiovascular disease in developing economies. New York, The Center for Global Health and Economic Development, 2004. The Earth Institute, Columbia University, https:\/\/www.eldis.org\/document\/A18750, Accessed 28 Nov\u00a02019"},{"key":"3163_CR11","doi-asserted-by":"crossref","unstructured":"Nguyen L, Wright P, Nguyen TT, Schuiling N et al (2016) Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam, PLoS One","DOI":"10.1371\/journal.pone.0155699"},{"key":"3163_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1161\/01.HYP.0000097602.67134.4D","volume":"42","author":"HD Sesso","year":"2003","unstructured":"Sesso HD, Chen RS, L\u2019Italien GJ et al (2003) Blood pressure lowering and life expectancy based on a Markov model of cardiovascular events. Hypertension 42:885\u2013890","journal-title":"Hypertension"},{"key":"3163_CR13","doi-asserted-by":"crossref","unstructured":"Lakic D, Petrova G, Bogavac-Stanojevic N et al (2011) Impact of discounting in pharmacoeconomic modeling. A case study.\u00a0Biotechnol Biotechnol Equip\u00a025:2555\u20132558","DOI":"10.5504\/BBEQ.2011.0065"},{"key":"3163_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.284.4.465","volume":"284","author":"HM Perry","year":"2000","unstructured":"Perry HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM et al (2000) Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 284:465\u2013471","journal-title":"JAMA"},{"key":"3163_CR15","unstructured":"Ward S (2005)\u00a0Statins for the prevention of coronary events. London: National Insititute for Clinical 16 Excellence"},{"issue":"15","key":"3163_CR16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547\u20131559","journal-title":"N Engl J Med"},{"issue":"9","key":"3163_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1524-6175.2006.05504.x","volume":"8","author":"MA Tedesco","year":"2006","unstructured":"Tedesco MA, Natale F, Calabro R (2006) Effects of monotherapy and combination therapy on blood 32 pressure control and target organ damage: a randomized prospective intervention study in a large 33 population of hypertensive patients. J Clin Hypertens 8(9):634\u2013641","journal-title":"J Clin Hypertens"},{"key":"3163_CR18","unstructured":"Spinar J, Vitovec J, Soucek M, Dusek L, Pavlik T\u00a0(2009)\u00a0Invesigators CORD. CORD: comparison of 17 recommended doses of ACE inhibitors and angiotensin II receptor blockers. Vnitrni Lekarstvi. 18 55(5):481\u2013488"},{"key":"3163_CR19","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation ( HOPE) Study Investigators (2000)\u00a0Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet\u00a0355(9200):253\u2013259","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"3163_CR20","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325(5):293-302","DOI":"10.1056\/NEJM199108013250501"},{"key":"3163_CR21","unstructured":"Croatian Health Insurance Fund (2018) Decision on the basis for the conclusion of the contract on health care provision from compulsory health insurance. Odluka o osnovama za sklapanje ugovora o provo\u0111enju zdravstvene za\u0161tite iz obveznog zdravstvenog osiguranja, NN 56\/2017, https:\/\/narodne-novine.nn.hr\/clanci\/sluzbeni\/2017_06_56_1235.html, Accessed 11 Dec\u00a02018"},{"key":"3163_CR22","unstructured":"MKB-10 (2012) World Health Organization, Medicinska naklada Zagreb, Zagreb"},{"key":"3163_CR23","unstructured":"WHO (2019) Collaborating Centre for Drug Statistic Methodology. Purpose of the ATC\/DDD system https:\/\/www.whocc.no\/atc_ddd_methodology\/purpose_of_the_atc_ddd_system\/, Accessed 24 May\u00a02019"},{"key":"3163_CR24","unstructured":"Harvard CEA Registry (1997)\u00a0Cost Effectiveness Analysis (CEA) Registry.  TuftsNew England Medical Center. https:\/\/research.tufts-nemc.org\/cear4\/Default.aspx"},{"key":"3163_CR25","unstructured":"Health Survey for England (1999)\u00a0Cardiovascular Disease. The Stationary Office"},{"issue":"5","key":"3163_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMsa1406751","volume":"372","author":"AE Moran","year":"2015","unstructured":"Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L (2015) Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 372(5):447\u2013455","journal-title":"N Engl J Med"},{"issue":"1","key":"3163_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1161\/HYPERTENSIONAHA.115.06814","volume":"68","author":"N Moise","year":"2016","unstructured":"Moise N, Huang C, Rodgers A, Kohli-Lynch CN, Tzong KY, Coxson PG et al (2016) Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35\u201374 years: the cardiovascular disease policy model. Hypertension 68(1):88\u201396","journal-title":"Hypertension"},{"key":"3163_CR28","doi-asserted-by":"crossref","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, Lancet, 24 Oct\u00a02019","DOI":"10.1016\/S0140-6736(19)32317-7"},{"key":"3163_CR29","doi-asserted-by":"crossref","unstructured":"Madsen TE, Howard G, Kleindorfer DO, Furie KL, Oparil S, Manson JE, Liu S, Howard VJ (2019) Sex differences in hypertension and stroke risk in the REGARDS study: a longitudinal cohort study. Hypertension\u00a074(4):749\u2013755","DOI":"10.1161\/HYPERTENSIONAHA.119.12729"},{"key":"3163_CR30","unstructured":"Hypertension in adults: diagnosis and management (2019)\u00a0https:\/\/www.guidelines.co.uk\/cardiovascular\/nice-hypertension-guideline\/454934.article, Accessed 2 Nov\u00a02019"},{"key":"3163_CR31","unstructured":"NICE clinical guideline 127 (2011) Hypertension: clinical management of primary hypertension in adults.\u00a0August 2011  www.nice.org.uk\/guidance\/CG127"},{"issue":"10","key":"3163_CR32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.amjcard.2009.12.068","volume":"105","author":"AR De Caterina","year":"2010","unstructured":"De Caterina AR, Leone AM (2010) Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol 105(10):1433\u20131438","journal-title":"Am J Cardiol"},{"key":"3163_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/5584_2016_36","volume":"956","author":"JM Cruickshank","year":"2017","unstructured":"Cruickshank JM (2017) The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol 956:149\u2013166","journal-title":"Adv Exp Med Biol"},{"key":"3163_CR34","doi-asserted-by":"crossref","unstructured":"Musini VM, Nazer M, Bassett K, Wright JM (2014) Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev.  29 May 2014","DOI":"10.1002\/14651858.CD003824.pub2"},{"key":"3163_CR35","doi-asserted-by":"crossref","unstructured":"Park C, Wang G, Durthaler JM, Fang J (2017) Cost-effectiveness analyses of antihypertensive medicines: a systematic review.\u00a0Am J Prev Med 53(6S2):S131\u2013S142.","DOI":"10.1016\/j.amepre.2017.06.020"},{"key":"3163_CR36","doi-asserted-by":"crossref","unstructured":"Kucan M, Mrsic-Pelcic J, Vitezic D (2018) Antihypertensive drugs in Croatia: what changes the drug usage patterns? Clinical Therapeutics, 40(7):1159\u20131169","DOI":"10.1016\/j.clinthera.2018.05.018"},{"key":"3163_CR37","first-page":"213","volume":"48","author":"RS Stafford","year":"2006","unstructured":"Stafford RS, Monti V, Furberg CD, Ma J (2006) Long-term and short- term changes in antihypertensive prescribing by office- based physicians in the United States Hypertension 48:213\u2013218","journal-title":"Long-term and short- term changes in antihypertensive prescribing by office- based physicians in the United States Hypertension"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03163-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:12:30Z","timestamp":1635239550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03163-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3163"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03163-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}